151 research outputs found
Genomics and molecular analysis of RPL9 and LIAS in lung cancer : emerging implications in carcinogenesis
Worldwide, lung cancer is a leading cause of cancer-related deaths and is the most commonly diagnosed form of
cancer. A major characteristic of lung cancer is its profound clinical, histological and molecular heterogeneity.
This heterogeneity is not only spatial but also temporal thus stressing the need for personalized patient-tailored
treatment planning. The current optimal treatment planning is currently based on real-time monitoring of the
evolving molecular profiling of the tumour throughout the course of the disease and treatment. In the current
work, we will investigate the emerging role that that RPL9 and LIAS could have in carcinogenesis. While the
aberrant expression of RPL9 has already been shown to occur in colorectal cancer its role in lung cancer is not yet
known. In a similar manner, the role of LIAS, as a metabolism-linked gene, in cancer biology and especially in
lung cancer is still unknown. Emerging research reveals both RPL9 and LIAS as interacting partners and apoptosis
resistance genes. The aim of this study is to determine the differential expression of the rpl9 and lias genes in both
normal lung tissue and lung cancer samples. This was achieved by using in situ hybridization (ISH) and quantitative
Real-time PCR (qPCR). Further data on the role played by RPL9 in lung cancer was established through
the use of in silico bioinformatic analysis. This was done in order to map biological pathways enriched by the
expression of these genes. Both the KEGG pathway and Reactome analysis confirmed the role of these genes in
RNA metabolic pathways. Furthermore, RPL9 was shown to play a role in signal transduction, autophagy, and
cellular response to stress pathways. The function of these two proteins overlapped with regard to protein
metabolism. STRING analysis also demonstrated an interaction between RPL9 and LIAS. Here we propose that
the aberrant expression of RPL9 and LIAS may contribute to lung carcinogenesis and can be targeted for molecular
therapy.Appendix A. Supplementary dataThe South African Medical Research Council (SAMRC) and the National Research Foundation (NRF).https://www.elsevier.com/locate/imuam2022Medical Virolog
3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants
Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer
Background Accurate predictions of tumor dissemination risks and medical treatment outcomes are critical to personalize therapy. Patient-derived xenograft (PDX) models in mice have demonstrated high accuracy in predicting therapeutic outcomes, but methods for predicting tumor invasiveness and early stages of vascular/lymphatic dissemination are still lacking. Here we show that a zebrafish tumor xenograft (ZTX) platform based on implantation of PDX tissue fragments recapitulate both treatment outcome and tumor invasiveness/dissemination in patients, within an assay time of only 3 days. Methods Using a panel of 39 non-small cell lung cancer PDX models, we developed a combined mouse-zebrafish PDX platform based on direct implantation of cryopreserved PDX tissue fragments into zebrafish embryos, without the need for pre-culturing or expansion. Clinical proof-of-principle was established by direct implantation of tumor samples from four patients. Results The resulting ZTX models responded to Erlotinib and Paclitaxel, with similar potency as in mouse-PDX models and the patients themselves, and resistant tumors similarly failed to respond to these drugs in the ZTX system. Drug response was coupled to elevated expression of EGFR, Mdm2, Ptch1 and Tsc1 (Erlotinib), or Nras and Ptch1 (Paclitaxel) and reduced expression of Egfr, Erbb2 and Foxa (Paclitaxel). Importantly, ZTX models retained the invasive phenotypes of the tumors and predicted lymph node involvement of the patients with 91% sensitivity and 62% specificity, which was superior to clinically used tests. The biopsies from all four patient tested implanted successfully, and treatment outcome and dissemination were quantified for all patients in only 3 days. Conclusions We conclude that the ZTX platform provide a fast, accurate, and clinically relevant system for evaluation of treatment outcome and invasion/dissemination of PDX models, providing an attractive platform for combined mouse-zebrafish PDX trials and personalized medicine
Microbiomics in collusion with the nervous system in carcinogenesis : diagnosis, pathogenesis and treatment
The influence of the naturally occurring population of microbes on various human diseases
has been a topic of much recent interest. Not surprisingly, continuously growing attention is
devoted to the existence of a gut brain axis, where the microbiota present in the gut can affect the
nervous system through the release of metabolites, stimulation of the immune system, changing the
permeability of the blood–brain barrier or activating the vagus nerves. Many of the methods that
stimulate the nervous system can also lead to the development of cancer by manipulating pathways
associated with the hallmarks of cancer. Moreover, neurogenesis or the creation of new nervous
tissue, is associated with the development and progression of cancer in a similar manner as the blood
and lymphatic systems. Finally, microbes can secrete neurotransmitters, which can stimulate cancer
growth and development. In this review we discuss the latest evidence that support the importance
of microbiota and peripheral nerves in cancer development and dissemination.The South African Medical Research Council (SAMRC).https://www.mdpi.com/journal/microorganismsam2022Surger
Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway
Background: reovirus exploits aberrant signalling downstream of Ras to mediate tumor-specific oncolysis. Since ~90% squamous cell carcinomas of the head and neck (SCCHN) over-express EGFR and SCCHN cell lines are sensitive to oncolytic reovirus, we conducted a detailed analysis of the effects of reovirus in 15 head and neck cancer cell lines. Both pre- and post-entry events were studied in an attempt to define biomarkers predictive of sensitivity/resistance to reovirus. In particular, we analysed the role of EGFR/Ras signalling in determining virus-mediated cytotoxicity in SCCHN. Methods: to test whether EGFR pathway activity was predictive of increased sensitivity to reovirus, correlative analyses between reoviral IC50 by MTT assay and EGFR levels by western blot and FACS were conducted. Inhibition or stimulation of EGFR signalling were analysed for their effect on reoviral oncolysis by MTT assay, and viral growth by TCID50 assay. We next analysed the effects of inhibiting signalling downstream of Ras, by specific inhibitors of p38MAPK, PI3-K or MEK, on reoviral killing examined by MTT assay. The role of PKR in reoviral killing was also determined by blockade of PKR using 2-aminopurine and assaying for cell survival by MTT assay. The apoptotic response of SCCHN to reovirus was examined by western blot analysis of caspase 3 cleavage. Results: correlative analyses between reoviral sensitivity and EGFR levels revealed no association. Intermediate sub-viral and core particles showed the same infectivity/cytotoxicity as intact reovirus. Therefore, sensitivity was not determined by cell entry. In 4 cell lines, oncolysis and viral growth were both unaffected by inhibition or stimulation of EGFR signalling. Inhibition of signalling downstream of Ras did not abrogate reoviral oncolysis and, in addition, modulation of PKR using 2-aminopurine did not alter reovirus sensitivity in resistant cell lines. Caspase 3 cleavage was not detected in infected cells and oncolysis was observed in pan-caspase inhibited cells. Conclusions: in summary, reovirus is potently oncolytic in a broad panel of SCCHN cell lines. Attempts to define sensitivity/resistance by analysis of the EGFR/Ras/MAPK pathway have failed to provide a clear predictive biomarker of response. Further analysis of material from in vitro and clinical studies is ongoing in an attempt to shed further light on this issue
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
BACKGROUND:
Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific therapy for an outbreak infection such as SARS-CoV-2. Findings from randomised clinical trials of hIVIG for the treatment of COVID-19 are limited.
METHODS:
In this international randomised, double-blind, placebo-controlled trial, hospitalised patients with COVID-19 who had been symptomatic for up to 12 days and did not have acute end-organ failure were randomly assigned (1:1) to receive either hIVIG or an equivalent volume of saline as placebo, in addition to remdesivir, when not contraindicated, and other standard clinical care. Randomisation was stratified by site pharmacy; schedules were prepared using a mass-weighted urn design. Infusions were prepared and masked by trial pharmacists; all other investigators, research staff, and trial participants were masked to group allocation. Follow-up was for 28 days. The primary outcome was measured at day 7 by a seven-category ordinal endpoint that considered pulmonary status and extrapulmonary complications and ranged from no limiting symptoms to death. Deaths and adverse events, including organ failure and serious infections, were used to define composite safety outcomes at days 7 and 28. Prespecified subgroup analyses were carried out for efficacy and safety outcomes by duration of symptoms, the presence of anti-spike neutralising antibodies, and other baseline factors. Analyses were done on a modified intention-to-treat (mITT) population, which included all randomly assigned participants who met eligibility criteria and received all or part of the assigned study product infusion. This study is registered with ClinicalTrials.gov, NCT04546581.
FINDINGS:
From Oct 8, 2020, to Feb 10, 2021, 593 participants (n=301 hIVIG, n=292 placebo) were enrolled at 63 sites in 11 countries; 579 patients were included in the mITT analysis. Compared with placebo, the hIVIG group did not have significantly greater odds of a more favourable outcome at day 7; the adjusted OR was 1·06 (95% CI 0·77–1·45; p=0·72). Infusions were well tolerated, although infusion reactions were more common in the hIVIG group (18·6% vs 9·5% for placebo; p=0·002). The percentage with the composite safety outcome at day 7 was similar for the hIVIG (24%) and placebo groups (25%; OR 0·98, 95% CI 0·66–1·46; p=0·91). The ORs for the day 7 ordinal outcome did not vary for subgroups considered, but there was evidence of heterogeneity of the treatment effect for the day 7 composite safety outcome: risk was greater for hIVIG compared with placebo for patients who were antibody positive (OR 2·21, 95% CI 1·14–4·29); for patients who were antibody negative, the OR was 0·51 (0·29–0·90; pinteraction=0·001).
INTERPRETATION:
When administered with standard of care including remdesivir, SARS-CoV-2 hIVIG did not demonstrate efficacy among patients hospitalised with COVID-19 without end-organ failure. The safety of hIVIG might vary by the presence of endogenous neutralising antibodies at entry.
FUNDING:
US National Institutes of Health
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Efficacy and safety of everolimus in advanced low- to intermediate-grade neuroendocrine tumors.
Adhesion molecules as targets for the treatment of neoplastic diseases
The quest for therapeutic specificity is implicit in all branches of
medicine. In cancer treatment, cytotoxic agents, such as chemotherapy
and radiotherapy, comprise the current therapeutic modality.
Unfortunately, when used against most solid malignancies, their
therapeutic indices are relatively low due to the significant damage
they inflict on normal tissues. Furthermore, cure rates have remained
essentially static over the last two decades. Specificity in killing
neoplastic cells, while sparing healthy ones is therefore the only
alternative approach, with several molecules qualifying as candidates
for targeting therapy. Reduction of cell-cell and cell-matrix adhesion
are, early tumorigenesis events also implicated in the invasive and
metastatic process. The fact that abnormal adhesive marker expression is
a feature commonly shared by most malignancies, along with its tendency
to occur as both an early and late event in neoplastic development,
makes these molecules potential candidates for antineoplastic targeted
therapies. This review presents the perspectives of specific
anti-adhesion molecule targeting as a possible therapeutic approach in
neoplastic diseases
- …